Farmaceutisk sammensætning til behandling af invasiv pulmonal aspergillose
摘要
<p>The present invention provides a pharmaceutical composition comprising purified human mannan-binding lectin (MBL) optionally along with carriers administered at a unit dose in the range of 1.0 mug-5.0 mug/20 kg body weight. Further, it also deals with a method and use thereof for the treatment of invasive pulmonary aspergillosis using said composition.</p>
